8-K: Chrome Holding Secures $10M Sale for Lemonaid Health

Chrome Holding Co., currently undergoing Chapter 11 bankruptcy, has entered into a definitive agreement to sell its Lemonaid telehealth business to Bambumeta Ventures for $10 million in cash.

Summary

• Chrome Holding Co. (the Company) and its subsidiaries (the Debtors) filed for Chapter 11 bankruptcy on March 23, 2025.
• On July 14, 2025, the Debtors sold substantially all of their assets to 23andMe Research Institute for $302.5 million in cash, plus assumption of certain liabilities.
• The Lemonaid telehealth business, including Lemonaid Health Inc. and Chrome Pharmacy Holdings, Inc. (collectively, the Lemonaid Companies), remained owned by the Debtors after the initial asset sale.
• Initially, 23andMe Research Institute (formerly TTAM Research Institute) had agreed to acquire Lemonaid Health for $2.5 million.
• A higher offer was subsequently received from Bambumeta Ventures, LLC.
• On September 10, 2025, the Company entered into a Stock Purchase Agreement with Bambumeta Ventures to sell 100% of the outstanding capital stock of the Lemonaid Companies.
• The total purchase price for the Lemonaid Companies is $10 million in cash, in addition to payments necessary to cure defaults under assumed contracts (Cure Payments).
• Bambumeta Ventures has provided a $2.5 million good faith deposit, which will be credited to the Purchase Price.
• The sale is subject to Court approval, confirmation of a Chapter 11 plan of reorganization, and receipt of certain regulatory approvals related to pharmacy licenses.
• The agreement includes termination rights if the closing does not occur by December 1, 2025, with a potential extension to January 30, 2026.

Sentiment

Score: 7

Explanation: The higher sale price for a key asset is a positive development for the company in bankruptcy, indicating better asset realization. However, the company remains in Chapter 11 with significant risks for shareholders.

Positives

• Secured a significantly higher purchase price of $10 million for the Lemonaid Companies, compared to the previously disclosed offer of $2.5 million.
• The sale represents a further step in the Debtors' Chapter 11 reorganization process, providing additional liquidity.
• The transaction includes a $2.5 million good faith deposit, demonstrating buyer commitment.

Negatives

• The Company remains in Chapter 11 bankruptcy, indicating ongoing financial distress.
• Trading in the Company's Class A common stock is highly speculative and poses substantial risks, with little or no relationship to actual recovery for holders.
• Uncertainty remains regarding Court approval of the sale and the overall outcome of the Chapter 11 Cases.

Risks

• Risks and uncertainties relating to the Chapter 11 Cases, including obtaining Court approval for motions and the sale itself.
• The effects of the Chapter 11 Cases on the Company and the interests of various constituents.
• The length of time the Company will operate under Chapter 11 and risks associated with third-party motions.
• Adverse effects of the Chapter 11 Cases on liquidity, results of operations, and increased legal/professional costs.
• Trading price and volatility of the Common Stock, and the continuation of trading on the OTC Pink Market.
• Uncertainty regarding the liquidity of an active trading market for the Common Stock and the prices investors may obtain.

Future Outlook

The Company's future outlook is focused on obtaining Court approval for the sale of the Lemonaid Companies, confirming a Chapter 11 plan of reorganization, and completing the transaction. Significant uncertainties remain regarding the outcome of the Chapter 11 Cases and the recovery for common stock holders.

Industry Context

This transaction reflects ongoing consolidation and asset divestitures within the telehealth and digital health sectors, particularly for companies undergoing financial restructuring. The sale of a telehealth business in bankruptcy highlights the challenges faced by some players in a competitive and evolving market, while also demonstrating the continued value of established platforms to strategic buyers.

Legal Proceedings

• The Company and its subsidiaries are currently operating under Chapter 11 of Title 11 of the United States Bankruptcy Code (the Chapter 11 Cases) in the United States Bankruptcy Court for the Eastern District of Missouri.

Related Party Transactions

• Substantially all of the Debtors' assets were previously sold to 23andMe Research Institute (formerly known as TTAM Research Institute). The Company's former name was 23andMe Holding Co., suggesting a potential related party relationship with the initial asset buyer.

Stakeholder Impact

• Shareholders: Trading in the common stock is highly speculative, with substantial risks and potential for little or no recovery in the Chapter 11 Cases.
• Creditors: The asset sale contributes to the pool of assets available for distribution to creditors as part of the Chapter 11 reorganization.
• Employees (of Lemonaid Companies): Will transition under the new ownership of Bambumeta Ventures, subject to the terms of the sale.

Next Steps

• Obtain approval from the United States Bankruptcy Court for the Eastern District of Missouri for the Stock Purchase Agreement and the Sale.
• Entry of a Court order confirming a Chapter 11 plan of reorganization for the Debtors.
• Occurrence of the effective date of the Chapter 11 plan.
• Performance by each party of its obligations under the Stock Purchase Agreement.
• Receipt of certain regulatory approvals related to the transfer of pharmacy licenses.
• Closing of the Sale, expected by December 1, 2025, or potentially extended to January 30, 2026.

Key Dates

Recommendation

While the higher sale price for Lemonaid Health is a positive development, the company remains in Chapter 11 bankruptcy, making its common stock highly speculative with substantial risks and uncertain recovery for shareholders. A 'hold' recommendation acknowledges the positive step while emphasizing the significant ongoing risks and the speculative nature of the investment during bankruptcy proceedings.

Keywords

Chrome Holding Co., Lemonaid Health, Bambumeta Ventures, Chapter 11, Bankruptcy, Asset Sale, Telehealth, Stock Purchase Agreement, SEC Filing, 8-K, Corporate Restructuring